Shanghai Zhongtuo Pharmaceutical

Shanghai Zhongtuo Pharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, focused on the discovery and development of innovative small molecule therapeutics for metabolic and inflammatory diseases. The company's lead candidate, ZT-001, is a highly selective URAT1 inhibitor currently in Phase 2 clinical trials for the treatment of hyperuricemia and gout. Shanghai Zhongtuo aims to provide superior treatment options by optimizing the safety and efficacy profiles of its drug candidates compared to existing therapies. The company is headquartered in the Zhangjiang Hi-Tech Park and is supported by leading venture capital firms such as Qiming Venture Partners and TF Capital. Its research and development efforts are directed toward addressing significant unmet medical needs in the global metabolic disease market.